Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Syncona Limited LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 195.00 195.00 198.00 - 2,971 08:03:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 25.4 15.5 2.3 83.3 1,305

Syncona Share Discussion Threads

Showing 18701 to 18722 of 18900 messages
Chat Pages: 756  755  754  753  752  751  750  749  748  747  746  745  Older
DateSubjectAuthorDiscuss
05/2/2020
10:37
What causes that type of spike?
1seanshare
05/2/2020
09:29
Looks like a very successful Capital Markets Day judging by the share price movement
ltinvestor
04/2/2020
09:46
Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life sciences, announces the appointment of Lorenz Mayr, Ph.D. as Entrepreneur in Residence, from 1 January 2020. In this role, he will have a particular focus on sourcing new Syncona companies, developing and driving portfolio company business plans and strategy. Lorenz has 25 years of experience in the pharmaceutical and biotechnology industry, spanning drug discovery and clinical development in areas including molecular biology, molecular imaging, antibodies, cell and gene therapy, and gene editing. Lorenz was most recently Chief Technology Officer at GE Healthcare, where he was responsible for leading the company’s global R&D strategy. Prior to this, he held senior leadership roles at AstraZeneca Plc, Novartis Pharma AG and Bayer AG. Lorenz is a lecturer for Biochemistry at the Martin-Luther University, Germany, and is a member of several Scientific Advisory Boards. Martin Murphy, Chief Executive of Syncona Investment Management Limited, said: “Lorenz is a highly regarded member of the scientific community and is a fantastic addition to the Syncona team. His knowledge and experience in the sector will enhance our search for best-in-class science that has commercial prospects and the potential to make meaningful differences to patients.” Lorenz Mayr, Entrepreneur in Residence of Syncona Investment Management Limited, added: “I look forward to joining the team at Syncona and helping them seek opportunities to found new companies. Syncona has an excellent track record and I’m excited to be part of a process that brings exceptional science from concept to clinic.”
sev22
04/2/2020
09:40
Life sciences company investor Syncona said its net asset value total return had crept up 0.2% in its fiscal third quarter. The rise had slightly reduced to 7.0% the fall in the company's net asset value total return for the nine months through December. Syncona's life science portfolio was valued at £516.6m at the end of December, up from £481.3m at the end of September. A total of £39.m of capital was deployed in the quarter and £167.1m over the nine months from the end of March. 'We have had a productive third quarter, funding Freeline as it continues to scale and leading a financing in a new Syncona company, Azeria, where there is an exciting opportunity to build a world-class oncology company,' Syncona Investment Management chief executive Martin Murphy said. 'We have also seen strong clinical progress across the portfolio with Autolus, Freeline and Gyroscope progressing seven clinical trials.' "We continue to take a hands-on approach to capitalise on the significant opportunities ahead.' 'We have a strong pipeline of opportunities to found new companies and will ambitiously fund our growing portfolio.'
sev22
01/2/2020
16:12
My bad, Capital Markets Day should read Tuesday, not Monday.
tiger blue
31/1/2020
11:47
Don't forget the Capital Markets Day on Monday from 13:00. Was going to attend but they are showing a live webcast (requires registration) which saves a trip to London. Pleased to see that the opening address will be by the Chair of the Wellcome Trust which underlines my belief that they will remain a long term supportive holder having already taken their cost out. There will be no inside info but nevertheless it will provide valuable insight into all of Syncona's existing projects and future vision, and a very rare opportunity to see some of the leading experts and founders such as Martin Pule (Autolus and whose work was the subject of the BBC programme) discuss their work and where the science is today.
tiger blue
31/1/2020
10:08
I'm trying to find some details on competitor products. Yescarta – 51% of patients had complete recovery from DLBCL measured at 7.9 months median (101 patients) AUTO3 – 57% of patients had the same at approx. 6 months median (18 patients). While Yescarta has the ‘normal’ potentially fatal side effects, AUTO3 has the safety ‘off switch’.
luxaeterna1
30/1/2020
16:27
These results seem extremely encouraging...
ltinvestor
30/1/2020
14:29
AUTO3 update online in text format. Looks like 18 patients. 57% complete response (71% partial response). Those achieving complete response appear to maintaining that for moderate time duration.
luxaeterna1
24/1/2020
08:53
The problem so far with Car T therapy is toxicity which Autolus have overcome by building in an “on” “ off” switch mechanism.I believe that Auto1 has been designated “orphan drug status” by the FDA and should therefore be producing revenues by the year end. Lymphoblastic leukaemia in children costs for a single treatment of Kymriah around $475k( Novartis)
ltinvestor
23/1/2020
16:04
There are 3 CAR-Ts already on the market treating some of those diseases mentioned. There are many others about to launch, all claiming small advantages based on production quality, ease of administration (which is a current real headache), and efficacy / safety. Who knows how this market will eventually play out but it’s clear now that the early promise has been a bit tempered, mainly based on less than expected efficacy (which had unrealistically high expectations) and difficulty of administration
1seanshare
23/1/2020
09:05
Looks like Auto 1could be in the marketplace by year end.Expecting significant revenues from just this one product alone....
ltinvestor
17/1/2020
12:12
I feel that AUTO is struggling against increased competition - lots of players in this space, as well as the science moving quickly...
1seanshare
17/1/2020
12:12
I feel that AUTO is struggling against increased competition - lots of players in this space, as well as the science moving quickly...
1seanshare
17/1/2020
12:09
Ok thanks, getting older, so prefer less risky investments, but I'll hold for now.
chc15
17/1/2020
11:59
Unclear CHC, average annual growth is 30% per year over the last 3 years, it probably overshot to £3 which was a significant premium to NAV. Currently trading about level with NAV. Quite a lot of things going on....AUTO or Freeline progress would significantly change the valuation.
luxaeterna1
17/1/2020
11:51
Any point holding onto these, not doing much, money put better eleswere?
chc15
21/12/2019
09:58
New AUTL presentation up on the website (Dec 19th) hxxps://www.autolus.com/investor-relations/news-and-events/presentations
luxaeterna1
19/12/2019
09:39
Healthcare company Syncona said it had made an $80m (£61.1m) funding commitment to biotech company Freeline. The first tranche of $40m tranche would allow Freeline to expand its team, continue to develop its manufacturing platform generate further data in its clinical programmes for Haemophilia B and Fabry Disease, and progress its pipeline, Sycona said on Thursday. Freeline has a pipeline of four disclosed programmes, two of which are clinical stage. Syncona chief investment officer and Freeline executive chairman Chris Hollowood said: 'Freeline has developed a high-quality gene therapy platform with a novel capsid capable of driving high expression levels to treat systemic diseases. 'We are encouraged by the potential product profile in our lead programme in Haemophilia B and believe Freeline has the opportunity to achieve functional cures for patients across a broad pipeline of systemic diseases.' Syncona said it would have a 79% fully diluted ownership stake in Freeline at the point full current commitments were invested.
brexitplus
19/12/2019
07:54
Excellent progress being made by Freeline which is 79% owned by Syncona and valued at cost!
ltinvestor
10/12/2019
15:12
Interesting appointment of Julia Gregory to the board of Freeline. With experience in investment banking and taking biotech's to IPO it suggests that they will be preparing for an IPO. Optimists view is that the Haemophilia B trial is looking good (read out due this financial year) and an IPO will be required to fund the Phase III. Syncona shares seem to have dropped as a result though?
milehouse
10/12/2019
10:19
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced the appointment of Julia P Gregory, to its Board of Directors. Ms. Gregory is a seasoned biopharmaceutical executive with CEO, CFO, Corporate Development, Board and Investment Banking experience. “We are delighted to welcome Julia to Freeline’s Board of Directors,” said Chris Hollowood, Executive Chairman of Freeline. “She brings significant experience in biopharma governance, operations and investment banking. I look forward to working with her as we build the Company and progress our innovative gene therapy programmes through the clinic and towards commercialisation.” “I am very pleased to be joining Freeline at this exciting time as the company brings curative gene therapies to patients suffering from the likes of Hemophilia, Fabry disease and Gaucher disease,” said Julia Gregory. “I look forward to working with the Board and management team to realise the full potential of these transformative therapies.” Currently Chair and CEO of Isometry Advisors, Inc., a biotechnology advisory company, Ms. Gregory also serves as a non-executive director of several biopharmaceutical companies, including Biohaven Therapeutics, Cell Medica, Iconic Therapeutics, IMV, Nurix Therapeutics, and Sosei-Heptares. She is also a senior advisor to the Morgan Stanley’s Private Equity Growth Fund and M. M. Dillon & Co., Inc. In her previous executive roles, Ms. Gregory served as Chief Executive Officer, Chief Financial Officer and Board Director of ContraFect Corporation; President and CEO of Five Prime Therapeutics; and Executive Vice President, Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. Her corporate development experience includes leading transactions for significant strategic partnerships including development and licensing agreements with GlaxoSmithKline, Human Genome Sciences, Genentech, Bristol-Myers Squibb Company and Takeda Pharmaceutical Company Limited. As CFO at Lexicon, she led the company’s $220 million public offering and was involved in the creation of Lexicon’s $500 million private equity plan with Invus, LLP. Prior to her leadership positions in the biopharmaceutical industry, Ms. Gregory was an investment banker at Dillon, Read & Co. and subsequently at Punk, Ziegel & Company, where she served as the head of investment banking and head of its life sciences practice. She received her B.A. in International Affairs from George Washington University ‘s Elliot School of International Affairs where she was elected to Phi Beta Kappa and her M.B.A. from The Wharton School of The University of Pennsylvania.
brexitplus
Chat Pages: 756  755  754  753  752  751  750  749  748  747  746  745  Older
ADVFN Advertorial
Your Recent History
LSE
SYNC
Syncona
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220817 07:25:45